Toferson Fails to Improve Motor Functions in Patients With SOD1 ALS
Toferson alone does not significantly change function in patients with faster progressing SOD1 amyotrophic lateral sclerosis.
Source: neurologyadvisor.com
Page 9 - Rating Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rating Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rating Scale Today - Breaking & Trending Today
Treatment with Own Cells Offers Degenerative Disease Hope
Enhancing the number and function of a patient’s own regulatory T-lymphocytes may slow progression of the degenerative disease amyotrophic lateral sclerosis (ALS), an early study suggests.
Source: insideprecisionmedicine.com
Press Release: Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
29.09.2022 - Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 ...
Source: wallstreet-online.de
Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
/PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory...
Source: prnewswire.com
FDA Panel Votes in Favor of Fixed-Dose Combination Therapy for ALS
The FDA panel voted in favor of the approval of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of amyotrophic lateral sclerosis.
Source: empr.com